February - 2015 - issue > CIO Insights

Invest in Relevant Solutions To Excell

By Mayur Danait , CIO, Lupin Limited
Thursday, February 12, 2015
By Mayur Danait , CIO, Lupin Limited
Mumbai based Lupin Ltd. (LUPIN.NS) (LUPIN.BO) is a transnational pharmaceutical company which is the second largest Indian pharmaceutical company by market capitalization. The current market cap of the company is Rs.65,971.69 Crore.

Leading players in the Indian Generics pharma industry have seen tremendous growth the last few years. We have seen organic entities of Indian players grow at a rapid pace in emerging and advanced markets. A lot of the growth has also been through acquisitions. What has got Indian pharma to this point might not necessarily take it further. Players will have to build technology expertise in newer areas to reinvent themselves as niche or specialty generics players. At the same time, regulatory pressure continues to build - patient safety is paramount, and regulatory bodies can only be expected to tighten the screws to ensure that.

What does all of this mean to the industry in general and the Information Technology function in particular?

The three core aspects of the business are developing drugs, getting the regulatory approvals and then manufacturing and bringing them to the customers. The following are the key areas where technology can be expected to make an impact.

Faster Time to Market, Better Systems to Manage New Drug Launches

Share on Twitter
Share on LinkedIn
Share on facebook